Given that KRAS mutations are prevalent in almost 30% of non-small cell lung cancer (NSCLC) patients [2], we chose a KrasG12D-driven spontaneous lung cancer murine model to elucidate the detailed mechanism by which DDX3X regulates lung cancer progression, which might be also extended to KRAS wildtype lung cancers. This evidence concerns the gene DDX3X and lung cancer.